FMP
PolyPid Ltd.
PYPD
NASDAQ
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
3.17 USD
-0.0642 (-2.03%)
Ms. Dikla Czaczkes Akselbrad
Healthcare
Biotechnology
NASDAQ
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
0001611842
IL0011326795
M8001Q118
18 Hasivim Street
972 7 4719 5700
IL
59
Jun 26, 2020
Mr. Ori Warshavsky
Chief Operating Officer - US
340.89k
1978
Ms. Dalit Hazan
Deputy Chief Executive Officer and Execu...
272.38k
1971
Mr. Jonny Missulawin
Chief Financial Officer
186.96k
1987
Mr. Tal Vilnai
General Counsel & Corporate Secretary
0
N/A
Ms. Dikla Czaczkes Akselbrad
Chief Executive Officer & Director
347.88k
1973
Ms. Maria Rubin
Vice President of Operations
0
N/A
Ms. Rivi Lev-ari
Vice President of Human Resource
0
N/A
Dr. Jean-Marc Hagai Pharm.D.
Chief Commercial Officer
0
N/A
As of December 31, 2024, the total employee count stands at 59, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.